SG Americas Securities’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-4,761
| Closed | -$485K | – | 3311 |
|
|
2023
Q2 | $485K | Sell |
4,761
-3,797
| -44% | -$359K | ﹤0.01% | 1405 |
|
|
2023
Q1 | $778K | Buy |
8,558
+1,606
| +23% | +$94.2K | 0.01% | 1354 |
|
|
2022
Q4 | $264K | Sell |
6,952
-1,115
| -14% | -$38.4K | ﹤0.01% | 2020 |
|
|
2022
Q3 | $203K | Sell |
8,067
-909
| -10% | -$25.2K | ﹤0.01% | 2313 |
|
|
2022
Q2 | $273K | Buy |
+8,976
| New | +$268K | ﹤0.01% | 2446 |
|
|
2022
Q1 | – | Sell |
-4,981
| Closed | -$131K | – | 3588 |
|
|
2021
Q4 | $131K | Sell |
4,981
-8,580
| -63% | -$664K | ﹤0.01% | 2905 |
|
|
2021
Q3 | $1.36M | Buy |
13,561
+10,015
| +282% | +$1.17M | 0.01% | 1637 |
|
|
2021
Q2 | $502K | Buy |
3,546
+1,615
| +84% | +$182K | ﹤0.01% | 1943 |
|
|
2021
Q1 | $193K | Sell |
1,931
-8,805
| -82% | -$1.03M | ﹤0.01% | 2698 |
|
|
2020
Q4 | $1.33M | Buy |
10,736
+2,061
| +24% | +$271K | 0.01% | 1359 |
|
|
2020
Q3 | $845K | Buy |
8,675
+4,971
| +134% | +$621K | 0.01% | 1285 |
|
|
2020
Q2 | $578K | Sell |
3,704
-2,046
| -36% | -$311K | ﹤0.01% | 1958 |
|
|
2020
Q1 | $830K | Buy |
5,750
+3,034
| +112% | +$586K | 0.01% | 1429 |
|
|
2019
Q4 | $555K | Buy |
+2,716
| New | +$495K | 0.01% | 1684 |
|
|
2019
Q3 | – | Sell |
-2,553
| Closed | -$241K | – | 3292 |
|
|
2019
Q2 | $241K | Sell |
2,553
-383
| -13% | -$33.1K | ﹤0.01% | 2312 |
|
|
2019
Q1 | $251K | Sell |
2,936
-121
| -4% | -$10K | ﹤0.01% | 2407 |
|
|
2018
Q4 | $171K | Buy |
+3,057
| New | +$187K | ﹤0.01% | 2459 |
|
Other funds holding RETA
SG Americas Securities's RETA Position: Q3 2023 in Review
SG Americas Securities sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 4,761 shares — an estimated $485K sold.
SG Americas Securities first reported a position in RETA in Q4 2018 and held it in 17 quarters. The position peaked at $1.36M in Q3 2021. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- SG Americas Securities reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- SG Americas Securities sold 4,761 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $485K.
- SG Americas Securities first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2018 and held it in 17 quarters.
- SG Americas Securities's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.36M in Q3 2021.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on SG Americas Securities's 13F filing for Q3 2023, filed 13 Oct 2023.